ASX-LISTED marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products EBOS, has announced a record interim unaudited net profit of $76.7m for the six months to 31 Dec 2017, with EBITDA up 15.6% and net profit after tax up 11.5%.
Shareholders will find their earnings per share up 11.0% to 50.4 cents.
EBOS ceo Patrick Davies said in the ASX announcement, "Our record first half results are in line with our expectations and reflect a consistent positive momentum across both our Healthcare and Animal Care businesses.
"During the first half, we have fully transitioned HPS into the Group, further expanding our leading position in the institutional Healthcare market."
Davies added that the diversified portfolio demonstrated organic growth and the Animal Health business "performed strongly".
"In Healthcare, the rebranding of TerryWhite and Chemmart pharmacies to TerryWhite Chemmart is now largely complete," he explained.
Other highlights were the acquisition in Oct of a 14.1% shareholding in MedAdvisor, the performance of consumer brand Red Seal and the launch of Black Hawk veterinary brand.
Davies said the strong start anticipates underlying EBITDA for FY2018 to grow approximately 10% over the prior year.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 18